Blood Screening Market by Product (Reagents & Kits, Instruments, Software), Technology (NAAT [Real-time PCR], ELISA [CLIA, FIA, CI], Rapid Tests, Western Blotting, NGS), and End User (Blood Banks, Hospitals, Laboratories)?Global Forecast to 2027
The blood screening market is expected to grow at a CAGR of 6.9% from 2020 to 2027 to reach $3.56 billion by 2027.
Following a comprehensive secondary and primary study and an in-depth analysis of the market scenario, the report provides the key drivers, restraints, challenges, and opportunities for the blood screening market. The main driving factors are increasing blood donations and transfusion-related screening, the rising prevalence of infectious diseases, the growing geriatric population, and increasing awareness regarding transfusion-transmitted diseases. Furthermore, factors such as emerging markets in developing and underdeveloped countries and the development and adoption of advanced technologies are expected to create high-growth opportunities for market players during the forecast period.
However, factors such as the lack of legislation, regulations, and policies related to blood collection and the development of alternative technologies to replace blood screening are expected to hinder the growth of this market to some extent.
Based on product, the reagents & kits segment commanded the largest market share in 2020, due to the wide range of diagnostic applications of various NAT and ELISA kits, the recurring cost of reagents, and the increasing prevalence of infectious diseases worldwide.
Based on technology, the nucleic acid amplification segment accounted for the largest share of this market in 2020. The large share of this segment is mainly attributed to the superiority of this technology in early disease detection due to its high sensitivity and specificity.
Based on end user, the blood banks segment accounted for the largest share of this market in 2020. This segment’s large share is attributed to factors such as increasing blood donations, increased awareness of transfusion-borne diseases, and the growing prevalence of infectious diseases.
An in-depth analysis of the geographical scenario of the blood screening market provides detailed qualitative and quantitative insights for five major geographies (North America, Europe, Asia-Pacific, the Middle East & Africa, and Latin America) along with the coverage of major countries in each region. In 2020, North America commanded the largest share of the blood screening market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
The key players operating in the blood screening market are Abbott Laboratories (U.S.), OriGene Technologies, Inc. (U.S.), BioAim Scientific Inc. (Canada), bioM?rieux, Inc. (France), Bio-Rad Laboratories, Inc. (U.S.), Grifols, S.A. (Spain), Immuno-Biological Laboratories Co., Ltd. (Japan), Biovision, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Boster Biological Technology (U.S.), Cusabio Technology LLC (U.S.), Danaher Corporation (U.S.), Demeditec Diagnostics GmbH (Germany), and F. Hoffmann-La Roche Ltd. (Switzerland), among others.
Scope of the Report:
Blood Screening Market, by Product
• Reagents & Kits
o NAT Kits & Reagents
o ELISA Kits & Reagents
o Other Kits & Reagents
• Software & Services
Blood Screening Market, by Technology
• Nucleic Acid Amplification
o Transcription Mediated Amplification (TMA)
o Real-time PCR
o Chemiluminescence Immunoassay (CLIA)
o Fluorescence Immunoassay (FIA)
o Colorimetric Immunoassay (CI)
• Rapid Tests
• Western Blotting
• Next-generation Sequencing (NGS)
Blood Screening Market, by End User
• Blood Banks
• Clinical Laboratories
Blood Screening Market, by Geography
• North America
? Rest of Europe (RoE)
? Rest of APAC (RoAPAC)
• Latin America
• Middle East & Africa